Symphogen and Cambridge Antibody Technology sign Patent Licensing Agreement

Symphogen A/S has entered into a patent license agreement with UK-based Cambridge Antibody Technology, CAT.

Under the terms of the agreement, Symphogen is granted a license to use CAT´s antibody phage display patents for research purposes and to develop and commercialise a number of therapeutic and diagnostic antibody products. Upon signing the agreement, Symphogen made an upfront payment for the license and exercised its first product license option to develop and commercialise its lead product Sym001. As a condition of exercising this option, Symphogen paid a product license fee and may make future milestone and royalty payments to CAT.

Sym001 is a recombinant, fully human, anti Rhesus D polyclonal antibody, which Symphogen is developing for Idiopathic Thrombocytopenic Purpura and Haemolytic Disease of newborns.

Symphogen A/S is a biotechnology company, which pioneers therapeutic products based on natural human antibodies for the treatment and prevention of human disease. Antibody drug candidates are generated using either Symplex or Symphage technologies and the selected lead candidate may be polyclonal or monoclonal, depending on the nature of the target. The company applies its proprietary expression platform, Sympress technology, for consistent manufacturing of recombinant polyclonal antibody compositions, termed symphobodies. Symphobodies offer a number of advantages over current plasma-derived immunoglobulins and monoclonal antibody therapies for the treatment of diseases characterised by complex target antigens, such as those found in infectious diseases, allergy, transplant rejection and cancer.

For further information please contact:

Kirsten Drejer,

CEO

Tel: +45 45 26 50 50

Email: kd@symphogen.com

Or visit: http://www.symphogen.com